High-intent comparisons for readers who have already narrowed the field and need to choose. Every comparison scores both compounds on evidence, safety, legal/access, and hype gap, and names the cases where one clearly wins.
Currently published
- Semaglutide vs Tirzepatide vs Retatrutide — the three most-discussed GLP-1 class compounds, compared on evidence, safety, cost, and what the market gets wrong.
Coming soon
- BPC-157 vs TB-500
- CJC-1295 vs Ipamorelin
- Semaglutide vs Liraglutide
- Retatrutide vs Tirzepatide head-to-head
How we compare
Every comparison article uses the same structure: quick verdict → best fit by goal → evidence comparison → safety comparison → legal and access comparison → practical complexity → hype gap → bottom line. The goal is to help the reader make a decision, not to hide behind "it depends" language.
See our methodology for the full evaluation framework.